Ipsen (IPN FP) CEO says that they are considering potential US manufacturing investment for plant to make neuroscience drugs

Statements of intent about potential US manufacturing investment from European pharma chiefs have become a recurring feature of the tariff cycle, and the pattern in comparable episodes is that the announcement value outweighs the near-term capex reality. Such comments are typically read first as positioning against threatened sectoral tariffs on pharmaceutical imports, where onshoring commitments have historically served as the negotiating currency that buys exemptions or delay. The distinction that matters is between a firm commitment with a site, timeline and capital figure and a conditional 'considering', which carries no balance sheet consequence and has often preceded lengthy evaluation rather than construction. Ipsen's framing around a neuroscience plant narrows the exposure to a specific franchise rather than group-wide production, which limits the read-across even if confirmed. The follow-ons are whether the comment hardens into a disclosed project, any parallel rhetoric from US officials on pharma tariffs, and whether peers with similar US revenue exposure make matching commitments, since clustered announcements have tended to mark the negotiating phase of these episodes. As a single conditional remark, the signal is strategic rather than financial.